Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 33 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

12%

4 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

10 recruiting

Enrollment Performance

Analytics

Phase 1
20(60.6%)
Phase 2
9(27.3%)
Phase 3
2(6.1%)
Phase 4
2(6.1%)
33Total
Phase 1(20)
Phase 2(9)
Phase 3(2)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (33)

Showing 20 of 33 trials
NCT07565441Phase 1Not Yet Recruiting

Drug-Drug Interactions of JMKX003142 in Healthy Participants

Role: lead

NCT07470177Phase 1Not Yet Recruiting

A Study to Investigate the Effects of JMKX003142 on QTc Interval in Healthy Adults

Role: lead

NCT07463053Phase 1Not Yet Recruiting

Mass Balance and Absolute Bioavailability Study of JMKX003142 In Healthy Volunteers

Role: lead

NCT07459452Phase 2Not Yet Recruiting

Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis

Role: lead

NCT07402213Phase 3Not Yet Recruiting

Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.

Role: lead

NCT07208136Phase 1Recruiting

A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors

Role: lead

NCT07242274Phase 3Not Yet Recruiting

Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC

Role: lead

NCT06880848Phase 4Completed

Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China

Role: lead

NCT07181265Phase 1Not Yet Recruiting

Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects

Role: lead

NCT06670534Phase 2Recruiting

A Dose-finding Study of JMKX003142 in Treatment of Renal Edema

Role: lead

NCT06800651Phase 2Recruiting

Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Role: lead

NCT06946927Phase 1Recruiting

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

Role: lead

NCT06438757Phase 2Active Not Recruiting

Trial of JYB1904 in Patients With Allergic Asthma

Role: lead

NCT06949020Phase 2Not Yet Recruiting

A Dose-finding Study of JMKX003142 in Treatment of Cardiac Edema

Role: lead

NCT06740019Phase 1Recruiting

A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

Role: lead

NCT06832657Phase 1Not Yet Recruiting

Study of JMKX003948 Ophthalmic Suspension in Healthy Participants

Role: lead

NCT06664125Phase 2Recruiting

Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia

Role: lead

NCT06509334Phase 2Recruiting

Trial of JYB1904 in Chronic Spontaneous Urticaria.

Role: lead

NCT06658964Phase 1Not Yet Recruiting

Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy Subjects

Role: lead

NCT06549309Phase 1Recruiting

Trial of JMKX003801 in Healthy Participants

Role: lead